Senores Pharmaceuticals Limited has sustained its robust growth momentum in the third quarter of FY26, delivering strong financial and operational performance across its regulated, emerging, and branded generics businesses. 

 

The research-driven pharmaceutical company released its unaudited results for the quarter and nine months ended December 31, 2025.

 

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year. EBITDA jumped 86% to Rs. 54 crore, while profit after tax (PAT) surged 105% to Rs. 34 crore. For the nine-month period, consolidated revenue reached Rs. 474 crore, a 65% increase, with EBITDA of Rs. 138 crore and PAT of Rs. 85 crore, reflecting growth of 87% and 110%, respectively.

 

Operating cash flow strengthened further, generating Rs. 19 crore in Q3 and Rs. 51 crore for 9M FY26, aided by improved EBITDA-to-cash conversion.

 

Regulated Markets: Revenue from regulated markets hit Rs. 112.7 crore in Q3 FY26, up 60.5% year-on-year, while nine-month revenue rose 71.5% to Rs. 309.6 crore. EBITDA margin stood at 40%. During the quarter, Senores launched two new ANDAs with three strengths, bringing its portfolio to 46 approved ANDAs covering 137 strengths. Another 22 ANDAs with over 50 strengths are under development. Its CDMO/CMO portfolio includes 16 commercial products across 34 strengths.

 

Emerging Markets: The emerging markets business recorded its highest-ever quarterly revenue and EBITDA in Q3 FY26, with revenue up around 48% year-on-year and EBITDA margin jumping to ~13%, compared to ~1% in Q3 FY25. For 9M FY26, EBITDA margin stood at around 9%. Senores now has 450 approved products and 858 under registration across 40+ countries. Notably, the business has turned cash-flow positive, driven by a focus on niche, higher-value products.

 

Branded Generics: The India-focused branded generics segment saw revenue grow more than six-fold year-on-year in Q3 FY26. Several products are now supplied to large multi-specialty hospital chains nationwide, reflecting strong clinician adoption.

 

Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said, “Q3 FY26 marked another strong quarter for us, with healthy growth across revenues, profitability, and cash flows. Our regulated markets business continues to be the primary growth engine, supported by a deep ANDA pipeline and improving operating leverage.

 

"The acquisition of Apnar Pharmaceuticals has strengthened our manufacturing footprint and accelerated our scale-up plans. Integration is progressing faster than expected, and the business is already contributing positively.

 

"In emerging markets, our focus on niche products has translated into meaningful margin expansion and cash-flow positivity. The branded generics business in India is also gaining traction, with growing acceptance across leading hospital networks. We remain confident of delivering on our full-year guidance and sustaining this momentum in the coming quarters.”